Manages vasospastic angina confirmed. ANDA 77127, held by Osmotica Pharm US. Nifedipine.
As of Nov 16, 2026, ANDA 77127 (Nifedipine), held by Osmotica Pharm US, was first approved by FDA on Nov 21, 2005, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2005 | Original application | Approved | None posted |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine90MG · tablet, extended release;oral | Nifedipine | Rx |
| Jan 11, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 11, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 21, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters